Successful treatment of severe chronic cutaneous lupus with anifrolumab: A series of 6 cases
Eric H. Kowalski, Ania Stolarczyk, Christopher T. Richardson
Abstract
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune condition that encompasses several subtypes with varying morphologies but a shared pathogenesis and cytokine signature.1,2 CLE is often isolated to the skin; an additional 70% to 80% of patients with systemic lupus erythematosus (SLE) suffer from CLE during their disease course.3,4 Given its potential for permanent scarring and dyspigmentation, CLE carries a significant negative impact on quality of life.5,6 Management of CLE subtypes has traditionally consisted of preventive measures alongside combinations of topical and systemic immunosuppressive therapies.
Topics & Concepts
MedicineCutaneous Lupus ErythematosusDermatologyLupus erythematosusPathogenesisImmunologySystemic lupus erythematosusDiseasePathologyAntibodySystemic Lupus Erythematosus ResearchT-cell and B-cell ImmunologyMonoclonal and Polyclonal Antibodies Research